Rivaroxaban after laparoscopic cancer surgery

Reduction of thrombotic risk after surgery is a long-established clinical practice standard, but evidence is lacking in some specific settings. In this issue of Blood, Becattini et al(1) publish the results of PROLAPS-II, a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of extended prophylaxis with rivaroxaban after laparoscopic surgery for colorectal cancer.

Automated summary

The study published in Blood presents the results of PROLAPS-II trial, which investigated the efficacy and safety of extended prophylaxis with rivaroxaban after laparoscopic surgery for colorectal cancer.